Crossmark Global Holdings Inc. Buys 11,777 Shares of Galapagos NV (NASDAQ:GLPG)

Crossmark Global Holdings Inc. boosted its stake in shares of Galapagos NV (NASDAQ:GLPG - Free Report) by 31.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 49,163 shares of the biotechnology company's stock after buying an additional 11,777 shares during the period. Crossmark Global Holdings Inc. owned 0.07% of Galapagos worth $1,352,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in shares of Galapagos by 140.7% during the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 736 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Galapagos by 63.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company's stock worth $112,000 after buying an additional 1,510 shares during the period. Rhumbline Advisers grew its stake in shares of Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company's stock valued at $113,000 after buying an additional 814 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Galapagos by 65.6% in the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock valued at $185,000 after buying an additional 2,541 shares during the period. Finally, QRG Capital Management Inc. acquired a new position in Galapagos during the 3rd quarter worth about $247,000. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GLPG. Royal Bank of Canada cut their price target on Galapagos from $32.00 to $30.00 and set a "sector perform" rating on the stock in a report on Friday, November 1st. Barclays restated an "underweight" rating on shares of Galapagos in a research note on Thursday. Kepler Capital Markets downgraded shares of Galapagos from a "hold" rating to a "reduce" rating in a research note on Wednesday, November 20th. Finally, TD Cowen downgraded shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a research report on Thursday, January 9th. Four research analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat.com, Galapagos presently has a consensus rating of "Hold" and an average target price of $30.75.

Galapagos Trading Down 0.2 %

GLPG stock traded down $0.04 during trading on Friday, hitting $23.70. The stock had a trading volume of 292,690 shares, compared to its average volume of 215,526. The company's 50 day moving average price is $26.55 and its two-hundred day moving average price is $27.42. Galapagos NV has a 1-year low of $23.45 and a 1-year high of $40.34.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.